Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Ajaz Sheikh

Neurology Toledo, OH Medical Doctor

NPI 1932401221 CMS profile 1401029

2130 W. Central Avenue, Toledo, OH 43606

Open in the dashboard

General payments

$3,571

180 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Ajaz Sheikh of Toledo, OH is reported in the CMS Open Payments database as having received $3,571 across 180 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 62nd percentile of Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $438 29
2024 General $1,327 49
2023 General $563 31
2022 General $621 30
2021 General $312 21
2020 General $94 6
2019 General $215 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Ajaz Sheikh
  • Neurology median
  • Middle half of Neurology
  • National median

In program year 2025, general payments to Ajaz Sheikh were reported at $438. Among 11,022 Neurology profiles paid that year, the median was $457 and the middle half received between $118 and $2,344.

Show as a table
Year Ajaz Sheikh Neurology median Middle half National median
2019 $215 $474 $118–$2,177 $163
2020 $94 $367 $82–$2,309 $114
2021 $312 $438 $104–$2,547 $132
2022 $621 $442 $103–$2,388 $149
2023 $563 $464 $119–$2,312 $160
2024 $1,327 $468 $119–$2,323 $164
2025 $438 $457 $118–$2,344 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $464 38 payments
  2. Jazz Pharmaceuticals Inc. $392 13 payments
  3. UCB, Inc. $381 19 payments
  4. NeuroPace, Inc. $316 3 payments
  5. SK Life Science, Inc. $242 14 payments
  6. Neurelis, Inc. $233 13 payments
  7. Teva Pharmaceuticals USA, Inc. $152 7 payments
  8. Eisai Inc. $132 5 payments
  9. Celgene Corporation $121 7 payments
  10. Biocodex, Inc. $112 2 payments
  11. Other $1,026 59 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,235 175 payments
  2. Education $336 5 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $352 30 payments
  2. RNS Neurostimulator Kit $316 3 payments
  3. Briviact $290 12 payments
  4. XYREM $279 7 payments
  5. QULIPTA $249 19 payments
  6. VALTOCO $233 13 payments
  7. ZEPOSIA $121 7 payments
  8. DIACOMIT $112 2 payments
  9. Leqembi $66 3 payments
  10. WAKIX $65 1 payment
  11. Other $1,661 102 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 50 drugs

Part D claims

1,834

Median for Neurology: 833

Drug cost

$625,925

Median for Neurology: $202,670

Branded share of claims

25.9%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gamunex-C Immune Globul G/Gly/Iga Avg 46 Brand 27 $224,842
Nurtec Odt Rimegepant Sulfate Brand 52 $68,528
Rufinamide Generic 24 $37,019
Keppra Levetiracetam Brand 25 $32,242
Zonegran Zonisamide Brand 13 $30,527
Aimovig Autoinjector Erenumab-Aooe Brand 39 $30,382
Briviact Brivaracetam Brand 15 $27,244
Vimpat Lacosamide Brand 22 $26,128
Fycompa Perampanel Brand 23 $25,654
Xcopri Cenobamate Brand 16 $16,173

The 10 drugs with the highest cost, of 50 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 35 billing codes

Paid by Medicare

$60,960

Medicare's payments for the services billed

Medicare patients

381

Average age 70

Services billed

699

185 women, 196 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Diabetes 39%
Depression 39%
Ischemic heart disease 38%
Chronic kidney disease 35%
Heart failure 30%
Atrial fibrillation 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Briviact
  • UCB, Inc. $170
$170 15 —
VALTOCO
  • Neurelis, Inc. $120
$120 — —
XYREM
  • JAZZ PHARMACEUTICALS INC. $100
$100 — —
DIACOMIT
  • BIOCODEX, INC. $85
$85 — —
QULIPTA
  • AbbVie, Inc. $80
$80 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

180 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record